13-Jul-2026
Globe Newswire (Tue, 7-Jul 9:00 AM ET)
Globe Newswire (Tue, 26-May 9:00 AM ET)
The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference
Globe Newswire (Wed, 13-May 9:00 AM ET)
The Oncology Institute Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 4:05 PM ET)
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call
Globe Newswire (Mon, 27-Apr 9:00 AM ET)
Market Chameleon (Fri, 13-Mar 6:31 AM ET)
Market Chameleon (Fri, 14-Nov 5:30 AM ET)
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
Oncology Institute trades on the NASDAQ stock market under the symbol TOI.
As of July 13, 2026, TOI stock price climbed to $6.25 with 2,858,720 million shares trading.
TOI has a beta of 1.62, meaning it tends to be more sensitive to market movements. TOI has a correlation of 0.06 to the broad based SPY ETF.
TOI has a market cap of $624.89 million. This is considered a Small Cap stock.
Last quarter Oncology Institute reported $147 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.06.
In the last 3 years, TOI traded as high as $6.32 and as low as $.13.
The top ETF exchange traded funds that TOI belongs to (by Net Assets): VTI, IWM, VXF, IWO, FDLS.
TOI has outperformed the market in the last year with a price return of +117.8% while the SPY ETF gained +20.9%. TOI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +102.9% and +16.0%, respectively, while the SPY returned +10.5% and +2.8%, respectively.
TOI support price is $5.63 and resistance is $6.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TOI shares will trade within this expected range on the day.